Alisertib for Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01779843
Recruitment Status : Completed
First Posted : January 30, 2013
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
Amir Fathi, Massachusetts General Hospital

January 25, 2013
January 30, 2013
February 17, 2017
April 2013
November 2015   (Final data collection date for primary outcome measure)
  • Maximum Tolerated Dose of Alisertib in combination with 7+3 induction chemotherapy [ Time Frame: 2 years ]
    The maximum tolerated dose (MTD) of the aurora kinase A inhibitor alisertib (MLN8237) in combination with 7+3 induction chemotherapy in patients with acute myeloid leukemia
  • Evaluate safety and tolerability of alisertib, including number of adverse events and severity. [ Time Frame: 2 years ]
    The number and severity of adverse events associated with this treatment.
Same as current
Complete list of historical versions of study NCT01779843 on Archive Site
  • Severity and number of all trial-related toxicities [ Time Frame: 2 years ]
    To detect and categorize, according to severity, the cumulative incidences of drug related toxicities
  • Rates of response [ Time Frame: 2 years ]
    To determine the response rate, including rates of complete and partial remission
  • One-year relapse-free and overall survival [ Time Frame: 2 years ]
    To measure the one-year relapse-free and overall survival after treatment
  • Measurement of tumor mitotic index, Ki67 and cPARP statining, Pharmacodynamic parameters for aurora kinase A inhibition, during treatment [ Time Frame: 2 years ]
    To assess pharmacodynamic effects of aurora kinase A inhibition, including tumor mitotic index, Ki67 and cPARP staining
Same as current
Not Provided
Not Provided
Alisertib for Acute Myeloid Leukemia
A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia

This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it. As part of this research study, you will take alisertib in combination with idarubicin and cytarabine. Alisertib has not been approved by the FDA for your cancer. However, cytarabine and idarubicin have both been approved by the FDA for treatment of AML. It also means that the FDA has not approved giving alisertib with idarubicin and cytarabine for use in patients, including patients with your type of cancer.

Idarubicin and cytarabine are chemotherapy agents that are commonly used to treat individuals diagnosed with AML. Alisertib has been used in laboratory studies and those studies suggest that alisertib may slow down the spread of your cancer. It does this by blocking certain substances needed by the cancer cells to spread. In this study, researchers would like to combine alisertib with standard chemotherapy (cytarabine and idarubicin) in order to see if it can be given safely with chemotherapy in individuals with AML.

The primary purpose of this research study is to determine the highest dose that alisertib can be given with idarubicin and cytarabine without severe or unmanageable side effects. The dose identified in this study will be used in future research studies.

If you agree to take part in this study you will be asked to undergo some screening tests or procedures to find out if you can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not need to be repeated. These tests and procedures include: a medical history, physical exam, performance status, urine test, Electrocardiogram, Echocardiogram, blood tests and a bone marrow aspirate/biopsy. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study.

You will begin treatment with idarubicin, and cytarabine followed by alisertib several days later (on day 8). Not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses. The following assessments will be completed while on trial: physical exam, performance status, urine test, blood tests, bone marrow aspirate/biopsy.

The first part of the study procedure is called "induction". During induction you will be admitted to the hospital on an in-patient basis. You will receive cytarabine and idarubicin by IV (intravenously or through a vein). Cytarabine will be given by continuous IV infusion for seven days, beginning on Day 1. Idarubicin will be given once each day as an IV injection for a total of three days, beginning on the same day as cytarabine. If idarubicin is not available, you may receive a very similar chemotherapy in its place called daunorubicin. Alisertib will be given orally (by mouth) twice a day for one week. It will start on the second week of treatment.

A bone marrow biopsy will be performed at approximately 14 days after the start of chemotherapy. If the results of this biopsy detect residual leukemia in the bone marrow, your physicians may give you another round of induction therapy. However, this time, cytarabine will be given by continuous IV infusion for only five days, and idarubicin will be given once each day as an IV injection for a total of 2 days, again beginning on the same day as cytarabine.

If at the end of the first cycle of induction (whether you've received one round or two rounds of induction) the number of leukemia cells have not decreased as much as expected or desired, you will be removed from the study and given alternative options.

The second part of study procedure is called "consolidation". If you have achieved a remission after your induction phase, you are not a candidate for a bone marrow transplant, and you tolerated study drug well during induction, you may receive consolidation treatment. Soem participants may not receive consolidation therapy on this trial, based on the advice of their treating physician.

For consolidation, you will receive a higher dose of cytarabine than you did during induction. You will be hospitalized and cytarabine will be given daily as an IV infusion for five days. Alisertib will also be given during the consolidation phase of therapy. It will start at the end of the cytarabine administration and be given for a total of seven days. You may receive up to four cycles of consolidation treatment, depending on your disease and the discretion of your treating physician.

The third part of study procedures is called "maintenance". After the induction course of therapy, your physician may begin consolidation therapy. If this is the case, you will start maintenance therapy after finishing consolidation therapy. If consolidation is not done, the maintenance phase will start after induction.

During maintenance, you will take alisertib twice daily for a period of seven days, followed by a two week break without treatment. This one week of therapy, followed by two weeks off therapy, will be a 21-day cycle. It will be repeated until 12 months have passed from the start of the maintenance therapy phase. During this phase, participants will not receive other chemotherapies and will not be hospitalized for treatment. They will take alisertib at home and will be followed in clinic for monitoring. During the maintenance phase, we will continue to collect approximately 2 to 3 teaspoons of blood for research purposes intermittently on your visits to clinic.

After the final dose of the study drug we would like to keep track of your medical condition and overall health following the 12 months of alisertib. We may ask you questions about your general health, current medications, and disease status. We will also check on any new anticancer therapy you may have started.

Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Acute Myelogenous Leukemia
  • Drug: Cytarabine
  • Drug: Idarubicin
  • Drug: Alisertib
    Other Name: MLN8237
Experimental: Treatment

Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.

Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)

  • Drug: Cytarabine
  • Drug: Idarubicin
  • Drug: Alisertib
Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2016
November 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically confirmed, newly diagnosed acute myelogenous leukemia
  • Agree to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of MLN8237
  • Able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration

Exclusion Criteria:

  • Have received systemic antineoplastic therapy, including radiotherapy within 14 days of study treatment, with the exception of hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction
  • Pregnant or breastfeeding
  • Presence of "favorable" or "better risk" cytogenic prognosis
  • Prior allogeneic bone marrow or organ transplantation
  • Diagnosis of acute bilineal/biphenotypic leukemia
  • History of a different malignancy except if disease-free for at least 5 years and at low risk or recurrence; or cervical cancer in situ, basal cell or squamous cell carcinoma of the skin within the past 5 years
  • Uncontrolled intercurrent illness
  • HIV positive on combination antiretroviral therapy
  • Diagnosis of active hepatitis B or C
  • Current or history of congestive heart failure NYHA class 3 or 4, or documented diastolic or systolic dysfunction
  • Current or history of ventricular or life threatening arrhythmias or diagnosis of long QT syndrome
  • Known history of uncontrolled sleep apnea syndrome or other condition that could result in excessive daytime sleepiness
  • Requirement for constant administration of proton pump inhibitor, H2 antagonist or pancreatic enzymes
  • Systemic infection requiring IV antibiotic therapy within 14 days of first dose of study drug
  • Treatment with clinically significant enzyme inducers
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Amir Fathi, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Amir Fathi, MD Massachusetts General Hospital
Massachusetts General Hospital
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP